YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after a stretch of weak share performance, with the stock down 16% over the past month and 28% across the past 3 months. Short term momentum for Alnylam Pharmaceuticals has clearly c…
Lipocine LPCN is an emerging specialty pharmaceutical company focused on developing oral therapies for diseases with significant unmet medical needs. The company offers a mix of an approved commercial product, a potentially differentiated…
Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The transaction is expected to provide the rare-disease drugmaker with a meaningful inf…
Shares of Eton Pharmaceuticals ETON have gained about 108% over the past six months compared with the industry's 0.7% growth, fueled by growing investor confidence in the company's strong commercial execution, rapid revenue growth and an e…
Pacira BioSciences PCRX announced an exclusive agreement with Molteni Farmaceutici to distribute and commercialize Exparel (bupivacaine liposome injectable suspension) in the EU and the United Kingdom. Molteni is an Italian specialty pharm…
Global bond markets have just steadied after a sharp sell off that pushed US borrowing costs to levels last seen in 2002, which keeps reliable cash generation and robust finances firmly in focus. That backdrop puts financially solid health…
The Morning Bull - US Market Morning Update Friday, Oct, 2 2026 US stock futures are mixed in early trade, with E-mini S&P 500 contracts roughly flat while Nasdaq-100 futures edge higher. Investors are weighing strong factory readings from…
Dr. Rajeev Mohan sitting in his office, in conversation with Pete and Kari Shaw. – Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM D…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
RNA therapeutics are medicines that use RNA molecules to influence gene expression or protein production. Unlike many conventional drugs that act directly on proteins, RNA medicines can intervene earlier in the process by reducing disease-…
Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
Company Logo RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease Applications Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth D…
Alnylam Pharmaceuticals recently presented at Wells Fargo's 21st Annual Healthcare Conference in Boston and Morgan Stanley's 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and…
By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief…
Company Logo Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Oppo…
There's no way to spin Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock performance in 2026 in a positive light. It's been downright ugly. Alnylam's share price plunged more than 50% year-to-date earlier this summer and remains around 40% bel…
NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the clos…
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sh…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
[Sandisk four and eight GB Compact Flash Memory Cards] NoDerog The Nasdaq Composite Index (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) ended flat in the red on Friday for the second straight week. Following major Wall Street index…
Company Logo 170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR Treatment Dublin, Sept. 04, 2026 (GLOBE NEWSWIRE) --…
It has been about a month since the last earnings report for TG Therapeutics (TGTX). Shares have added about 15.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings relea…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthcar…
CAMBRIDGE, Mass., September 02, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor c…
Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con…
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discu…
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) on Sunday presented new analyses supporting the use of Amvuttra across a range of patients wit…
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baselin…
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed wi…
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell o…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Photo by geralt on Pixabay Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue. Moderna (MRNA) has returned about 486% over the trailing twelve months,…
BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t…
BridgeBio Pharma BBIO is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company's revenue base over the next year. The trade-off is a demanding valuation alongside conti…